Investment Rating - The industry investment rating is "Positive" [10] Core Insights - The report highlights strong performance in the beauty and personal care sector, particularly in the medical aesthetics and cosmetics segments, with notable revenue growth and profitability in key companies [9][41] - The report emphasizes the importance of emotional consumption and the demand for innovative products that meet consumer needs, particularly in the context of domestic brands gaining market share [44][45] Summary by Sections Market Review - The beauty care index rose by 2.75% in February, outperforming the broader market [15] - In the medical aesthetics sector, companies like Huahan Co. and Pumen Technology saw significant stock price increases, while in cosmetics, Qing Song Co. and Beitaini led the gains [6][25] Medical Aesthetics Performance - Jinbo Bio reported a revenue of 1.595 billion yuan for 2025, a year-on-year increase of 10.57%, but a net profit decline of 11.08% due to increased costs and strategic adjustments [7][31] - Huaxi Bio's revenue for 2025 was 4.217 billion yuan, down 21.49%, while net profit surged by 67.03% due to cost management and strategic realignment [34][34] Cosmetics Performance - The 38 promotional event showcased strong performance for domestic brands, with significant sales figures reported from live streaming channels [8][36] - Upme Co. projected a revenue of 9.1-9.2 billion yuan for 2025, reflecting a growth of 34.0%-35.4%, driven by its successful brand strategy [41][41] Investment Recommendations - The report recommends focusing on high-quality companies in the medical aesthetics and cosmetics sectors that cater to emotional consumption trends, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][44] - In cosmetics, brands that innovate with emotional value and safe ingredients are favored, with recommendations for companies like Porlaia and Upme Co. [45][46]

上海市锦天城律师事务所 地址：上海市浦东新区银城中路501号上海中心大厦11、12层 电话：021-2051 1000 传真：021-2051 1999 邮编：200120 上海市锦天城律师事务所 法律意见书 关于申联生物医药（上海）股份有限公司 2026年第一次临时股东会的 法律意见书 上海市锦天城律师事务所 关于申联生物医药（上海）股份有限公司 2026 年第一次临时股东会的 法律意见书 致：申联生物医药（上海）股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》、《上市公司股东会规则》及其他相关法律、法规、规章和规范 性文件，以及《申联生物医药（上海）股份有限公司章程》（以下简称"《公司 章程》"）等相关规定，上海市锦天城律师事务所（以下简称"本所"）接受申 联生物医药（上海）股份有限公司（以下简称"申联生物"或"公司"）的委托， 指派本所律师出席公司 2026 年第一次临时股东会（以下简称"本次股东会"）， 对本次股东会的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的包括但不限于如下相关文 件： 1. 公司现行有效的《公司章程 ...

证券代码：688098 证券简称：申联生物 公告编号：2026-009 申联生物医药（上海）股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 3 月 12 日 （二） 股东会召开的地点：上海市闵行区江川东路 48 号公司综合楼一楼会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股 东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 122 | | --- | --- | | 普通股股东人数 | 122 | | 2、出席会议的股东所持有的表决权数量 | 241,044,743 | | 普通股股东所持有表决权数量 | 241,044,743 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 59.1917 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 59.1917 ...

Financial Performance Summary - In 2025, the company achieved operating revenue of 288.27 million RMB, a decrease of 4.99% compared to the previous year [3] - The net profit attributable to the parent company was a loss of 19.09 million RMB, which represents a reduction in losses by 57.33% year-on-year [3] - Total assets at the end of the reporting period were 1.54 billion RMB, a decrease of 0.71% from the beginning of the year [3] - The equity attributable to the parent company was 1.39 billion RMB, down 1.47% from the beginning of the year [3] Operational Factors - The company continued to expand into new areas of biopharmaceutical technology, enhancing product market competitiveness and optimizing marketing strategies [4] - Despite increased sales volume due to entry into large aquaculture supply chains, revenue and gross margin slightly declined due to competitive pricing pressures in the animal health industry [4] - Delays in customer payments led to an increase in accounts receivable and higher credit impairment losses [4] - The company adjusted its operational strategy, focusing on customer needs and achieving progress in the development of multi-valent vaccines [4] Investment and Future Plans - The company invested in a stake in an innovative drug company, Yangzhou Shizhi Source Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [5] - The company plans to gain controlling interest in Shizhi Source through its wholly-owned subsidiary, Shanghai Bentiancheng Biotechnology Co., Ltd., integrating it into the consolidated financial statements [5] - Future plans include leveraging biotechnological advantages to accelerate the development and launch of innovative drugs, including treatments for HIV and allergy monoclonal antibodies [6] Credit Impairment Provision - The company plans to recognize a credit impairment provision of 12.76 million RMB for the year 2025 [11] - This provision is based on expected credit losses from accounts receivable, notes receivable, and other receivables [11] - The impact of this provision on the company's total profit for 2025 is estimated to be 12.76 million RMB, excluding tax effects [12]

Group 1 - The company, Shenlian Biological (688098.SH), reported a revenue of 288.27 million yuan for the fiscal year 2025, representing a decrease of 4.99% compared to the previous year [1] - The net profit attributable to the parent company's owners was -19.09 million yuan, showing an improvement in loss reduction by 57.33% year-on-year [1]

Group 1 - The core viewpoint of the article highlights that Shenlian Bio reported a revenue of approximately 288 million yuan for the year 2025, representing a year-on-year decrease of 4.99% [1] - The net profit attributable to shareholders of the listed company was a loss of 19.09 million yuan, compared to a loss of 44.74 million yuan in the same period last year [1] - The basic earnings per share for the company was a loss of 0.05 yuan, an improvement from a loss of 0.11 yuan in the previous year [1] Group 2 - The article also mentions a significant shift in AI usage, with China surpassing the United States in AI call volume, leading to a surge in various sectors in the A-share market [1] - A well-known Wall Street analyst commented on China's computing power path, suggesting it disrupts traditional perceptions [1]

Core Viewpoint - The company reported a revenue of approximately 288 million yuan for the fiscal year 2025, reflecting a year-on-year decline of 4.99%, while achieving a reduction in net loss to 19.09 million yuan [2] Group 1: Financial Performance - The company's revenue for 2025 was about 288 million yuan, down 4.99% compared to the previous year [2] - The net profit attributable to the company was a loss of 19.09 million yuan, indicating a reduction in losses year-on-year [2] Group 2: Operational Insights - The reduction in losses was primarily due to impairment provisions made for ongoing projects in 2024 [2] - Despite intense competition in the industry, the company made positive progress in product and marketing efforts [2] - The company implemented more precise and effective cost control measures [2]

Group 1 - The core point of the article is that Shenlian Bio reported a decrease in revenue and a net loss for the year 2025 [2] - The company achieved total operating revenue of 288.27 million yuan in 2025, which represents a decrease of 4.99% compared to the previous year [2] - The net profit attributable to the owners of the parent company was a loss of 19.09 million yuan [2]

Group 1 - The core point of the article is that Shenlian Biological has reported a decline in revenue and a net loss for the fiscal year 2025, although the loss has decreased compared to the previous year [1] Group 2 - The company achieved an operating income of 288 million yuan, representing a year-on-year decrease of 4.99% [1] - The net profit attributable to shareholders was a loss of 19.09 million yuan, which is a reduction in loss by 57.33% year-on-year [1] - The basic earnings per share were -0.05 yuan, showing an increase of 54.55% compared to the previous year [1]

证券代码：688098 证券简称：申联生物 公告编号：2026-008 申联生物医药（上海）股份有限公司 关于 2025 年度计提信用减值准备的公告 | 项目 | 金额 | 备注 | | --- | --- | --- | | 信用减值损失 | 1,275.70 | 应收账款、应收票据、其他 | | | | 应收款坏账准备 | 二、本次计提信用减值准备事项的具体说明 公司以预期信用损失为基础，对应收账款、应收票据和其他应收款进行了减 值测试并确认减值损失。经测试，2025年度公司计提信用减值损失金额共计 1,275.70万元。 三、本次计提信用减值准备对公司的影响 2025年度公司合并报表口径计提信用减值损失1,275.70万元，对公司2025年 度合并报表利润总额的影响额为1,275.70万元（不包含所得税影响）。本次计提 信用减值损失数据未经审计，最终以会计师事务所年度审计确认的金额为准。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次计提减值准备情况概述 根据《企业会计准则》以及公司会计政策、会计估计的相关规定， ...